
Opinion|Videos|September 25, 2024
Optimal Timing and Frequency of Imagining Agents Used in the Detection and Characterization of Oligometastatic Prostate Cancer
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Jaideep Sohi, MD, and Jeremie Calais, MD, conduct a comparative assessment of gallium-based and non-gallium-based imaging agents for their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- How do you determine the optimal timing and frequency of imaging studies using specific agents to monitor oligometastatic disease progression in prostate cancer patients?
Advertisement
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
Study: PSMA PET/CT Reduces Biopsy Rate by Nearly 50 Percent for Men with Equivocal or Non-Suspicious Prostate mpMRI
2
Addressing Challenges in Radiology Reporting
3
The Hidden Social Price of Remote Work in Radiology
4
Mammography Study: Can AI Detect Potential Breast Cancer Up to a Decade Prior to Diagnosis?
5












